US5217996A
(en)
*
|
1992-01-22 |
1993-06-08 |
Ciba-Geigy Corporation |
Biaryl substituted 4-amino-butyric acid amides
|
AR002945A1
(es)
*
|
1994-11-15 |
1998-05-27 |
Bayer Corp |
Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
|
DK0810991T3
(da)
*
|
1995-02-22 |
1999-10-25 |
Novartis Ag |
1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister
|
MY132550A
(en)
|
1996-08-22 |
2007-10-31 |
Novartis Ag |
Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
|
MXPA01009654A
(es)
*
|
1999-03-29 |
2002-05-14 |
Squibb Bristol Myers Co |
Uso de inhibidores de la vasopeptidasa para tratar la angina de pecho.
|
IL162661A0
(en)
*
|
2002-01-17 |
2005-11-20 |
Novartis Ag |
Pharmaceutical compositions comprising valsartan and nep inhibitors
|
US7468390B2
(en)
*
|
2002-01-17 |
2008-12-23 |
Novartis Ag |
Methods of treatment and pharmaceutical composition
|
GB0203061D0
(en)
*
|
2002-02-08 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
ATE550656T1
(de)
*
|
2003-08-20 |
2012-04-15 |
Alere San Diego Inc |
Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
|
EP1771169A1
(en)
*
|
2004-07-14 |
2007-04-11 |
PTC Therapeutics, Inc. |
Methods for treating hepatitis c
|
US7781478B2
(en)
*
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7868037B2
(en)
*
|
2004-07-14 |
2011-01-11 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
US7772271B2
(en)
*
|
2004-07-14 |
2010-08-10 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
AU2005275182A1
(en)
|
2004-07-22 |
2006-02-23 |
Ptc Therapeutics, Inc. |
Thienopyridines for treating Hepatitis C
|
MY146830A
(en)
*
|
2005-02-11 |
2012-09-28 |
Novartis Ag |
Combination of organic compounds
|
WO2007045663A2
(en)
*
|
2005-10-19 |
2007-04-26 |
Novartis Ag |
Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
|
RU2459809C2
(ru)
*
|
2005-11-09 |
2012-08-27 |
Новартис Аг |
Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
|
AR057882A1
(es)
*
|
2005-11-09 |
2007-12-26 |
Novartis Ag |
Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
|
EP1903027A1
(en)
*
|
2006-09-13 |
2008-03-26 |
Novartis AG |
Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
|
SI2121578T1
(sl)
|
2007-01-12 |
2016-12-30 |
Novartis Ag |
Postopek za pripravo 5-bifenil-4-amino-2-metil pentanojske kisline
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
TWI406850B
(zh)
*
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
EP2200975A1
(en)
|
2007-09-07 |
2010-06-30 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
AU2008307798B2
(en)
*
|
2007-10-05 |
2013-10-03 |
Verastem, Inc. |
Pyrimidine substituted purine derivatives
|
JP2011506459A
(ja)
|
2007-12-11 |
2011-03-03 |
セラヴァンス, インコーポレーテッド |
抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
|
AR070176A1
(es)
*
|
2008-01-17 |
2010-03-17 |
Novartis Ag |
Procesos de sintesis de inhibidores de nep, compuestos intermediarios y uso de los mismos en la sintesis
|
AU2012202949B2
(en)
*
|
2008-01-17 |
2015-01-22 |
Novartis Ag |
Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
|
WO2009134741A1
(en)
|
2008-04-29 |
2009-11-05 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101607875B
(zh)
*
|
2008-06-17 |
2012-07-25 |
中国石油化学工业开发股份有限公司 |
制造环烷酮的方法
|
WO2010011821A2
(en)
|
2008-07-24 |
2010-01-28 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101774941A
(zh)
*
|
2009-01-13 |
2010-07-14 |
浙江九洲药业股份有限公司 |
2-酰基氨基-3-联苯基丙酸的制备及拆分方法
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
KR101442897B1
(ko)
*
|
2009-05-28 |
2014-09-23 |
노파르티스 아게 |
네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체
|
CN102448928B
(zh)
*
|
2009-05-28 |
2014-10-01 |
诺华股份有限公司 |
作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
|
WO2011005674A1
(en)
|
2009-07-07 |
2011-01-13 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
EP2456762B1
(en)
|
2009-07-22 |
2013-10-16 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
US8481549B2
(en)
|
2010-01-19 |
2013-07-09 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
RU2564024C2
(ru)
*
|
2010-01-22 |
2015-09-27 |
Новартис Аг |
Промежуточные продукты для получения ингибиторов нейтральной эндопептидазы и способ их получения
|
US8835668B2
(en)
|
2010-08-23 |
2014-09-16 |
Novartis Ag |
Process for the preparation of intermediates for the manufacture of NEP inhibitors
|
PT2609071T
(pt)
*
|
2010-08-23 |
2016-12-26 |
Novartis Ag |
Novo processo para a preparação de intermediários úteis para o fabrico de inibidores de nep
|
RU2564941C2
(ru)
|
2010-08-24 |
2015-10-10 |
Новартис Аг |
Лечение гипертензии и/или предотвращение и лечение сердечной недостаточности у млекопитающего, получающего терапию антикоагулянтами
|
US8993631B2
(en)
*
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
US8673974B2
(en)
*
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
MX354476B
(es)
|
2010-12-15 |
2018-03-07 |
Theravance Inc |
Inhibidores de neprilisina.
|
AU2011343899B2
(en)
|
2010-12-15 |
2016-06-30 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
ES2564275T3
(es)
|
2011-02-17 |
2016-03-21 |
Theravance Biopharma R&D Ip, Llc |
Derivados aminobutíricos sustituidos como inhibidores de neprilisina
|
WO2012112742A1
(en)
*
|
2011-02-17 |
2012-08-23 |
Theravance, Inc. |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
US8686184B2
(en)
|
2011-05-31 |
2014-04-01 |
Theravance, Inc. |
Neprilysin inhibitors
|
CA2835216A1
(en)
|
2011-05-31 |
2012-12-06 |
Theravance, Inc. |
Neprilysin inhibitors
|
CN103582630B
(zh)
|
2011-05-31 |
2016-08-17 |
施万生物制药研发Ip有限责任公司 |
脑啡肽酶抑制剂
|
TWI560172B
(en)
|
2011-11-02 |
2016-12-01 |
Theravance Biopharma R&D Ip Llc |
Neprilysin inhibitors
|
AR089955A1
(es)
*
|
2012-02-15 |
2014-10-01 |
Theravance Inc |
Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
|
CA2871292A1
(en)
|
2012-05-31 |
2013-12-05 |
Theravance Biopharma R&D Ip, Llc |
Nitric oxide donor neprilysin inhibitors
|
AU2013271537B2
(en)
|
2012-06-08 |
2017-05-11 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
US8871792B2
(en)
|
2012-06-08 |
2014-10-28 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
JP6092390B2
(ja)
|
2012-08-08 |
2017-03-08 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
ネプリライシン阻害剤
|
CN108685889A
(zh)
|
2012-08-24 |
2018-10-23 |
诺华股份有限公司 |
用于治疗特征为心房增大或重构的疾病的nep抑制剂
|
CA2900226A1
(en)
|
2013-02-14 |
2014-08-21 |
Novartis Ag |
Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
|
DK2956464T3
(en)
|
2013-02-14 |
2018-07-16 |
Novartis Ag |
Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
|
WO2014127331A1
(en)
|
2013-02-17 |
2014-08-21 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
EP2964616B1
(en)
|
2013-03-05 |
2017-05-03 |
Theravance Biopharma R&D IP, LLC |
Neprilysin inhibitors
|
CN104230865B
(zh)
*
|
2013-06-13 |
2018-01-09 |
上海翰森生物医药科技有限公司 |
联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
|
PT3626270T
(pt)
|
2013-08-26 |
2024-01-11 |
Novartis Ag |
Tratamento de doenças cardiovasculares
|
EP3038653A1
(en)
|
2013-08-26 |
2016-07-06 |
Novartis AG |
New use
|
AU2015211041B2
(en)
|
2014-01-30 |
2018-11-08 |
Theravance Biopharma R&D Ip, Llc |
5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
|
CA2934936A1
(en)
|
2014-01-30 |
2015-08-06 |
Theravance Biopharma R&D Ip, Llc |
Neprilysin inhibitors
|
WO2015154673A1
(en)
*
|
2014-04-10 |
2015-10-15 |
Zhaoyin Wang |
Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
|
JP6591530B2
(ja)
|
2014-08-07 |
2019-10-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
CN105622452A
(zh)
*
|
2014-08-27 |
2016-06-01 |
上海翰森生物医药科技有限公司 |
Ahu-377结晶型游离酸及其制备方法和应用
|
CN105367438A
(zh)
*
|
2014-08-27 |
2016-03-02 |
上海翰森生物医药科技有限公司 |
AHU-377α-苯乙胺盐多晶型及其制备方法和应用
|
CN105461587A
(zh)
*
|
2014-08-27 |
2016-04-06 |
上海翰森生物医药科技有限公司 |
Ahu-377半钙盐晶型及其制备方法和应用
|
WO2016029828A1
(zh)
*
|
2014-08-27 |
2016-03-03 |
上海翰森生物医药科技有限公司 |
AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
|
WO2016037098A1
(en)
|
2014-09-04 |
2016-03-10 |
Concert Pharmaceuticals, Inc. |
Deuterated sacubitril
|
HUE046278T2
(hu)
|
2014-11-14 |
2020-02-28 |
Zentiva Ks |
Módszer AHU-377 gyógyszerészetben alkalmazható formáinak elõállítására, izolálására és tisztítására
|
CN105693543B
(zh)
*
|
2014-12-15 |
2018-08-10 |
四川海思科制药有限公司 |
沙库比曲类衍生物、其药物组合物、制备方法及用途
|
CN104557600B
(zh)
*
|
2015-01-26 |
2016-05-04 |
苏州明锐医药科技有限公司 |
沙库比曲的制备方法
|
US9433598B2
(en)
|
2015-02-11 |
2016-09-06 |
Theravance Biopharma R&D Ip, Llc |
(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
|
TW201632493A
(zh)
|
2015-02-13 |
2016-09-16 |
諾華公司 |
新穎方法
|
JP6714009B2
(ja)
|
2015-02-19 |
2020-06-24 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
(2r,4r)−5−(5’−クロロ−2’−フルオロビフェニル−4−イル)−2−ヒドロキシ−4−[(5−メチルオキサゾール−2−カルボニル)アミノ]ペンタン酸
|
WO2016135751A1
(en)
|
2015-02-25 |
2016-09-01 |
Mylan Laboratories Limited |
Novel process for the preparation of sacubitril and its intermediates
|
CN110801452B
(zh)
*
|
2015-03-12 |
2023-01-13 |
深圳信立泰药业股份有限公司 |
一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
|
WO2016150337A1
(zh)
*
|
2015-03-20 |
2016-09-29 |
苏州晶云药物科技有限公司 |
Ahu377的晶型及其制备方法与用途
|
HRP20230480T1
(hr)
|
2015-05-11 |
2023-07-21 |
Novartis Ag |
Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
|
WO2016193883A1
(en)
|
2015-05-29 |
2016-12-08 |
Novartis Ag |
Sacubitril and valsartan for treating metabolic disease
|
CN104860894B
(zh)
*
|
2015-06-10 |
2017-05-17 |
北京博全健医药科技有限公司 |
一种抗心衰药lcz696的制备方法
|
EP3828175A1
(en)
|
2015-06-12 |
2021-06-02 |
Teva Pharmaceuticals International GmbH |
Solid state forms of trisodium valsartan: sacubitril
|
WO2016203500A2
(en)
|
2015-06-19 |
2016-12-22 |
Actavis Group Ptc Ehf. |
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
CN107980038B
(zh)
*
|
2015-07-02 |
2021-04-27 |
诺华股份有限公司 |
沙库巴曲钙盐
|
WO2017006254A1
(en)
|
2015-07-08 |
2017-01-12 |
Novartis Ag |
Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
|
WO2017009784A1
(en)
|
2015-07-14 |
2017-01-19 |
Cadila Healthcare Limited |
Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
|
WO2017012600A1
(en)
|
2015-07-20 |
2017-01-26 |
Zentiva, K.S. |
A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
|
SI3325013T2
(sl)
|
2015-07-23 |
2023-11-30 |
Bayer Pharma Aktiengesellschaft |
Stimulatorji/aktivatorji topne gvanilat ciklaze v kombinaciji z zaviralcem NEP in/ali antagonistom angiotenzina II in njihova uporaba
|
WO2017029261A1
(de)
*
|
2015-08-19 |
2017-02-23 |
Bayer Pharma Aktiengesellschaft |
Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
|
WO2017033128A1
(en)
|
2015-08-25 |
2017-03-02 |
Novartis Ag |
Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
|
WO2017037577A1
(en)
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
New use
|
WO2017051326A1
(en)
|
2015-09-23 |
2017-03-30 |
Novartis Ag |
New processes and intermediates useful in synthesis of nep inhibitors
|
WO2017072636A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical synergistic combination
|
JO3771B1
(ar)
|
2015-12-10 |
2021-01-31 |
Novartis Ag |
متوسطات لتحضير ساكوبيتريل وتحضيرها
|
MX2018007129A
(es)
*
|
2015-12-11 |
2018-11-09 |
Zentiva Ks |
Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
|
CN106977417A
(zh)
*
|
2016-01-15 |
2017-07-25 |
常州方楠医药技术有限公司 |
一种沙库比曲钠盐的晶型及其制备方法
|
AU2017215530B2
(en)
|
2016-02-03 |
2019-09-12 |
Novartis Ag |
Galenic formulations of organic compounds
|
TWI731943B
(zh)
|
2016-03-08 |
2021-07-01 |
美商施萬生物製藥研發Ip有限責任公司 |
結晶型(2s,4r)-5-(5’-氯-2’-氟-[1,1’-聯苯]-4-基)-2-(乙氧基甲基)-4-(3-羥基異㗁唑-5-甲醯胺基)-2-甲基戊酸及其用途
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
CN105753733B
(zh)
*
|
2016-04-15 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
Ahu377的晶型及其制备方法与用途
|
CN105820064A
(zh)
*
|
2016-04-18 |
2016-08-03 |
浙江天宇药业股份有限公司 |
一种联苯基丙氨醇衍生物的合成方法及中间体
|
WO2017191620A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Sun Pharmaceutical Industries Limited |
A crystalline form of a salt of sacubitril and a process of its preparation
|
US20190256454A1
(en)
|
2016-07-05 |
2019-08-22 |
Novartis Ag |
New process for early sacubitril intermediates
|
CN107602399B
(zh)
*
|
2016-07-11 |
2020-09-25 |
江西东邦药业有限公司 |
一种脑啡肽酶抑制剂中间体的制备方法
|
EP3500549B1
(en)
|
2016-08-17 |
2020-12-16 |
Novartis AG |
New processes and intermediates for nep inhibitor synthesis
|
CN106318988B
(zh)
*
|
2016-08-23 |
2020-11-03 |
迪嘉药业集团有限公司 |
一种lcz696关键中间体的制备方法
|
EP3511317A4
(en)
|
2016-09-07 |
2020-04-15 |
Noratech Pharmaceuticals, Inc. |
NEW CRYSTALLINE SODIUM SALT FORM OF SACUBITRIL
|
CN106478437A
(zh)
*
|
2016-09-27 |
2017-03-08 |
南通常佑药业科技有限公司 |
一种γ‑氨基戊酸酯衍生物的制备方法
|
CN106496055A
(zh)
*
|
2016-10-09 |
2017-03-15 |
杭州科巢生物科技有限公司 |
一种抗心衰新药的关键组分沙库比曲的新合成方法
|
US10857132B2
(en)
|
2016-10-10 |
2020-12-08 |
Laurus Labs Limited |
Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
|
US10995060B2
(en)
|
2016-10-28 |
2021-05-04 |
Biocon Limited |
Amorphous Trisodium Sacubitril Valsartan and process for its preparation
|
US10774036B2
(en)
|
2016-12-23 |
2020-09-15 |
Novartis Ag |
Process for early sacubitril intermediates
|
CN106831473B
(zh)
*
|
2017-02-22 |
2019-07-16 |
江西瑞雅药业有限公司 |
3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
|
WO2018153895A1
(de)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
|
WO2018178295A1
(en)
|
2017-03-31 |
2018-10-04 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Stable hot-melt extrudate containing valsartan and sacubitril
|
WO2019020706A1
(en)
|
2017-07-28 |
2019-01-31 |
Synthon B.V. |
PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
|
US20200276129A1
(en)
|
2017-10-13 |
2020-09-03 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Tablet containing valsartan and sacubitril
|
CN108530371B
(zh)
*
|
2017-12-27 |
2020-09-01 |
浙江天宇药业股份有限公司 |
一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
GB201810326D0
(en)
*
|
2018-06-22 |
2018-08-08 |
Johnson Matthey Plc |
Crystalline form of sacubitril, its preparation and use
|
KR20210032437A
(ko)
|
2018-08-23 |
2021-03-24 |
노파르티스 아게 |
심부전의 치료를 위한 신규한 약제학적 용도
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN109503404A
(zh)
*
|
2018-12-28 |
2019-03-22 |
凯瑞斯德生化(苏州)有限公司 |
一种lcz-696关键中间体的制备方法
|
CN110128298B
(zh)
*
|
2019-06-13 |
2021-08-03 |
南京一心和医药科技有限公司 |
一种沙库巴曲中间体的合成方法
|
CN113135836A
(zh)
*
|
2020-01-20 |
2021-07-20 |
鲁南制药集团股份有限公司 |
一种沙库巴曲钙盐的制备方法
|
CN111253425B
(zh)
*
|
2020-02-21 |
2022-04-29 |
常州南京大学高新技术研究院 |
一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
|
JP7064527B2
(ja)
*
|
2020-05-01 |
2022-05-10 |
ノバルティス アーゲー |
サクビトリルカルシウム塩
|
KR20220012821A
(ko)
|
2020-07-23 |
2022-02-04 |
주식회사 종근당 |
이중 작용 복합 화합물의 결정형 및 이의 제조방법
|
CN112661671B
(zh)
*
|
2020-12-22 |
2022-04-22 |
江苏阿尔法药业股份有限公司 |
一种沙库巴曲中间体的制备方法
|
WO2022224274A1
(en)
|
2021-04-20 |
2022-10-27 |
Mylan Laboratories Limited |
Polymorphic forms of sacubitril-telmisartan (1:1)
|